Determining the Endometriosis Treatment Market Size requires a precise understanding of the global patient pool, treatment rates, and the average cost of different treatment modalities. The market valuation is a cumulative measure, aggregating the revenue from pharmaceutical sales (both chronic and acute usage), surgical equipment and consumables, and associated diagnostic tests. The substantial diagnostic delay and the large undiagnosed population mean that the addressable market size is far larger than the currently realized market size, representing a significant long-term growth opportunity. The market value is further inflated by the high price of specialty drugs, such as newer oral GnRH antagonists, and the advanced surgical systems used in excision surgery.

The market size calculation must also factor in the high rate of recurrence post-treatment, which necessitates repeated interventions, providing a consistent revenue stream for both the pharmaceutical and surgical segments. Economic models project that increasing awareness and earlier diagnosis will be the primary multipliers for the market size, converting the vast pool of undiagnosed individuals into treated patients. For stakeholders, accurately segmenting the market size by the severity of the disease (mild, moderate, severe) is key, as the required treatment complexity and, consequently, the cost and revenue generated, vary drastically across these groups.